BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Ordinary shares, par value $0.0001 per share
Symbol
ONC on Nasdaq
Shares outstanding
1,385,160,313
Price per share
$303.81
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
32,957,934
Total reported value
$11,225,971,347
% of total 13F portfolios
0%
Share change
-1,440,337
Value change
-$346,944,388
Number of holders
260
Price from insider filings
$303.81
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HHLR ADVISORS, LTD. 4.9% -26% $16,350,132,640 -$5,784,964,646 68,551,141 -26% HHLR Advisors, Ltd. 09 May 2025

As of 30 Sep 2025, 260 institutional investors reported holding 32,957,934 shares of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC). This represents 2.4% of the company’s total 1,385,160,313 outstanding shares.

Institutional Holders of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 27,407 $8,364,228 -$2,147,174 $303.81 27
2025 Q3 32,957,934 $11,225,971,347 -$346,944,388 $340.70 260
2025 Q2 34,445,503 $8,338,029,358 -$2,098,488,418 $242.07 240
2025 Q1 42,522,880 $11,571,290,738 -$300,778,228 $272.17 259
2024 Q4 43,643,682 $8,061,061,147 -$556,417,441 $184.71 220
2024 Q3 46,387,065 $10,410,403,172 -$140,709,553 $224.51 223
2024 Q2 46,778,251 $6,675,796,297 +$49,829,686 $142.67 196
2024 Q1 46,405,233 $7,257,217,531 +$233,916,446 $156.39 200
2023 Q4 34,825 $6,269,949 +$353,686 $180.36 3
2023 Q3 46,821,398 $8,423,244,830 -$8,973,572 $179.87 188
2023 Q2 46,934,709 $8,368,914,130 -$142,560,834 $178.30 194
2023 Q1 47,668,673 $10,275,560,122 -$365,876,712 $215.53 210
2022 Q4 49,303,290 $10,847,763,148 -$801,166,555 $219.94 201
2022 Q3 53,443,095 $7,207,039,667 -$15,592,248 $134.82 196
2022 Q2 53,401,007 $8,643,775,994 -$230,553,146 $161.85 210
2022 Q1 54,891,500 $10,363,536,114 -$131,504,847 $188.60 222
2021 Q4 51,627,354 $13,983,601,276 -$199,712,302 $270.93 236
2021 Q3 55,983,215 $20,320,686,326 +$170,640,736 $363.00 240
2021 Q2 55,460,687 $19,037,292,751 -$284,868,453 $343.19 258
2021 Q1 56,480,778 $19,491,865,606 +$714,575,012 $348.08 242
2020 Q4 53,149,942 $13,730,791,993 -$203,263,606 $258.39 226
2020 Q3 54,801,174 $15,693,904,741 +$1,342,169,395 $286.44 233
2020 Q2 49,117,793 $9,252,708,810 +$179,007,715 $188.40 198
2020 Q1 48,375,764 $5,955,755,286 +$14,284,553 $123.11 196
2019 Q4 48,835,643 $8,094,439,533 -$125,959,897 $165.76 211
2019 Q3 49,554,837 $6,068,202,908 +$318,868,575 $122.46 187
2019 Q2 48,664,075 $6,031,826,336 +$139,705,339 $123.95 191
2019 Q1 46,581,872 $6,147,792,912 +$72,927,441 $132.00 190
2018 Q4 47,308,130 $6,634,397,750 -$436,889,193 $140.26 184
2018 Q3 45,412,987 $7,821,189,762 +$587,472,536 $172.22 138
2018 Q2 42,021,663 $6,460,034,864 +$944,146,227 $153.73 124
2018 Q1 36,228,256 $6,086,285,344 +$1,500,008,672 $168.00 120
2017 Q4 27,567,001 $2,693,889,000 +$229,200,158 $97.72 93
2017 Q3 25,042,053 $2,590,841,144 +$489,058,371 $103.46 80
2017 Q2 20,398,866 $917,947,000 +$131,198,370 $45.00 56
2017 Q1 17,607,585 $644,614,000 +$43,545,154 $36.61 54
2016 Q4 16,604,419 $504,116,000 +$195,354,439 $30.36 54
2016 Q3 10,161,007 $313,122,000 +$58,303,870 $30.81 38
2016 Q2 8,275,571 $241,300,000 +$17,031,982 $29.80 38
2016 Q1 7,506,105 $219,924,000 +$219,924,064 $29.31 38